Microarray Analysis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Microarray Analysis Market is projected to grow from USD 5.68 Billion in 2025 to USD 9.23 Billion by 2031, registering a CAGR of 8.43%. Microarray analysis serves as a high-throughput technology that utilizes hybridization probes on a solid substrate to simultaneously detect the expression of thousands of genes or identify specific DNA sequences. The market's expansion is primarily driven by the rising prevalence of chronic diseases, such as cancer and genetic disorders, which necessitates rapid diagnostic screening. Furthermore, the burgeoning demand for personalized medicine and significant investments in pharmaceutical research for drug discovery continue to bolster industry growth, providing a solid foundation for long-term utility in genomic analysis and clinical diagnostics.

However, the market confronts a significant challenge due to intense competition from Next-Generation Sequencing technologies, which offer higher resolution and are becoming increasingly cost-effective. This competitive pressure is particularly acute as healthcare systems strive to manage the growing disease burden. According to the American Cancer Society, 2,041,910 new cancer cases are projected to occur in the United States in 2025, indicating a massive demand for genomic profiling that microarrays must vie to fulfill against newer, more advanced alternatives.

Market Drivers

The escalating prevalence of cancer and genetic disorders acts as a primary force propelling the adoption of microarray analysis. As clinicians and researchers strive to unravel the complex genetic underpinnings of malignancies, microarrays provide a critical platform for high-throughput gene expression profiling and comparative genomic hybridization. This technology facilitates the rapid identification of biomarkers and chromosomal aberrations essential for early detection and disease subtyping. According to the International Agency for Research on Cancer's February 2024 press release regarding the growing global cancer burden, there were approximately 20 million new cancer cases and 9.7 million deaths worldwide in 2022, necessitating robust genomic tools to support large-scale population screening and molecular pathology despite emerging competition.

Concurrently, the growing application of microarrays in pharmaceutical drug discovery and development is significantly fortifying market expansion. Pharmaceutical entities utilize these platforms extensively for target validation and toxicogenomics, enabling the assessment of drug safety and efficacy at the molecular level before clinical trials, which helps mitigate late-stage failures and streamlines the intensive R&D process. The scale of investment driving these activities is underscored by the European Federation of Pharmaceutical Industries and Associations' August 2024 report, which estimated that the research-based biopharmaceutical industry invested €50.00 billion in R&D in Europe in 2023. Furthermore, Illumina, Inc. generated $392 million in revenue specifically from its microarray segment during fiscal year 2023, reflecting the sustained commercial viability of this technology.

Market Challenges

The intensified competition from Next-Generation Sequencing (NGS) technologies constitutes a formidable barrier to the growth of the Global Microarray Analysis Market. Although microarrays provide a platform for simultaneous gene expression analysis, they lack the high-resolution capabilities of NGS, which can identify novel genetic variants and provide deeper genomic insights. As healthcare providers prioritize diagnostic precision, the diminishing cost gap between these technologies is accelerating the migration of testing volumes from microarrays to sequencing platforms. This substitution effect restricts the market’s addressable audience, confining microarrays to niche applications while NGS captures the lucrative segment of comprehensive disease profiling.

The impact of this technological shift is underscored by recent industry usage data. According to the College of American Pathologists, in November 2024, a study on clinical genomic reporting practices revealed that 100% of the reviewed oncology assays utilized targeted genomic panels rather than array-based methods. This entrenched preference for sequencing-based workflows in cancer diagnostics demonstrates how the superior utility of newer alternatives is directly eroding the market share of microarray technologies in critical clinical settings.

Market Trends

The rapid expansion of protein microarrays in proteomics research signifies a strategic shift beyond DNA analysis toward phenotypic characterization. Researchers utilizing high-throughput arrays can now decipher biological mechanisms that genomic data alone cannot reveal, driving adoption in large-scale population studies. This trend is exemplified by massive biobanking initiatives that leverage the multiplexing capabilities of modern biochips. According to a UK Biobank press release in January 2025 regarding the launch of a significant protein study, the organization announced a project to measure up to 5,400 proteins in each of 600,000 samples, highlighting the technology's growing centrality in biomarker discovery and drug development.

Concurrently, the integration of microarray workflows with Next-Generation Sequencing (NGS) is creating comprehensive multi-omic solutions. Key players are merging microarray-based affinity platforms with sequencing infrastructure to enable simultaneous interrogation of the genome and proteome, providing a holistic view of disease biology that isolated technologies cannot achieve. This consolidation is highlighted by recent strategic moves, such as Standard BioTools Inc.'s November 2025 financial results, which noted the sale of its SomaLogic business to Illumina, Inc. in June 2025. Such transactions illustrate the industry's push to unify microarray capabilities with sequencing ecosystems to enhance diagnostic precision.

Key Players Profiled in the Microarray Analysis Market

• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Illumina Inc.
• PerkinElmer Inc.
• Merck KGaA
• GE Healthcare Technologies, Inc.
• Danaher Corporation
• Arrayit Corporation
• Microarrays Inc.
• Bio-Rad Laboratories Inc.

Report Scope

In this report, the Global Microarray Analysis Market has been segmented into the following categories:

Microarray Analysis Market, by Product and Service:

• Consumable
• Software and Service
• Instruments

Microarray Analysis Market, by Type:

• DNA Microarrays
• Protein Microarrays
• others

Microarray Analysis Market, by Applications:

• Drug Discovery
• Disease Diagnostic
• Research Applications
• others

Microarray Analysis Market, by End-User:

• Research and Academic Institutes
• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• others

Microarray Analysis Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Microarray Analysis Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.